Letter to the editor [1]

Journal of Clinical Virology

Volumn 27, Issue 3, 2003, Pages 308-309

  Gross, G ^a   Doerr, H W ^b  

^a ROSTOCK UNIVERSITY MEDICAL CENTER   (Germany)

^b UNIVERSITY HOSPITAL FRANKFURT   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

5 (2 BROMOVINYL) 2' DEOXYURIDINE; ACICLOVIR; IMMUNOGLOBULIN A ANTIBODY; IMMUNOGLOBULIN M ANTIBODY; VIRUS ANTIGEN; ANTIVIRUS AGENT; BROXURIDINE; DRUG DERIVATIVE;

BLOOD SAMPLING; CANCER; CANCER RISK; CARCINOGENIC ACTIVITY; CELL PROLIFERATION; GENOTOXICITY; HERPES ZOSTER; HUMAN; LETTER; MUTAGENIC ACTIVITY; NONHUMAN; PRIORITY JOURNAL; VARICELLA ZOSTER VIRUS; VIRUS DETECTION; AGED; ANIMAL; CARCINOGEN TESTING; DERMATOLOGY; GERMANY; MEDICAL SOCIETY; MIDDLE AGED; MOUSE; NOTE; PRACTICE GUIDELINE; RAT;

AGED; ANIMALS; ANTIVIRAL AGENTS; BROMODEOXYURIDINE; CARCINOGENICITY TESTS; DERMATOLOGY; GERMANY; GUIDELINES; HERPES ZOSTER; HERPESVIRUS 3, HUMAN; HUMANS; MICE; MIDDLE AGED; RATS; SOCIETIES, MEDICAL;

EID: 0242348865     PISSN: 13866532     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1386-6532(03)00125-2     Document Type: Letter

References (10)

1. Breuer J. Commentary on herpes zoster guidelines of the German dermatological society. J. Clin. Virol. 26:2003;291-293.
2. Doerr H.W., Rentschler M., Schleifler G. Serologic detection of active infections with human herpes viruses (CMV, EBV, HSV, VZV): diagnostic potential of IgA class and IgG subclass specific antibodies. Infection. 15:1987;93-98.
3. Forghani B., Myoraku C.K., Dupuis K.W., Schmidt N.J. Antibody class capture assays for varicella-zoster virus. J. Clin. Microbiol. 19:1984;606-609.
4. Gross G., Schöfer H., Wassilew S., Friese K., Timm A., Guthoff R., Pau H.W., Malin J.P., Wutzler P., Doerr H.W. Herpes zoster guidelines of the German Dermatology Society (DDG). J. Clin. Virol. 26:2003;277-289.
5. Oshiro Y., Piper C.E., Soetter S.G., Balwierz P.S., Garriott M.L. Genotoxic properties of (E)-5-(2-Bromovinyl)-2′-deoxyuridine (BVDU). Fundam. Appl. Toxicol. 18:1992;491-498.
6. Prentice D.E., Meikle A.W. A review of drug-induced Leydig cell hyperplasia and neoplasia in the rat and some comparisons with man. Hum. Exp. Toxicol. 14:1995;562-572.
7. Tovi F., Hader T., Sidi X., Sarow B., Sarov I. The significance of specific IgA antibodies in the serum in the early diagnosis of zoster. J. Infect. Dis. 152:1985;230.
8. Wassilew SW, Stubinski BM, Koch I, Schumacher K, Städtler G. Brivudin compared with acyclovir and famciclovir: effect on zoster-associated pain, Antiviral Research 2001;50(1) A 90:180.
9. Wassilew SW, Wutzler P. on behalf of the Brivudin Herpes Zoster Study Group. Oral brivudin in comparison with acyclovir for improved therapy of herpes zoster in immunocompetent patients: results of a randomised, double-blind, multicentered study, Antiviral Research 2003a, in press.
10. Wassilew SW, Wutzler P. on behalf of the Brivudin Herpes Zoster Study Group. Oral brivudin in comparison with acyclovir for herpes zoster: a survey study on postherpetic neuralgia, Antiviral Research 2003b, in press.